Nikolaos Arkadopoulos

Dr. Nikolaos Arkadopoulos


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Maria Anthi KouriMaria Anthi Kouri
Maria Anthi Kouri
Ellas SpyratouEllas Spyratou
Ellas Spyratou
MKMaria Karnachoriti
Maria Karnachoriti
DKDimitris Kalatzis
Dimitris Kalatzis
NDNikolaos Danias
Nikolaos Danias
Efstathios P. EfstathopoulosEfstathios P. Efstathopoulos
Efstathios P. Efstathopoulos
Accurate in situ diagnosis and optimal surgical removal of a malignancy constitute key elements in reducing cancer-related morbidity and mortality. In surgical oncology, the accurate discrimination between healthy and cancerous tissues is critical for the postoperative care of the patient. Conventional imaging techniques have attempted to serve as adjuvant tools for in situ biopsy and surgery guidance. However, no single imaging modality has been proven sufficient in terms of specificity, sensitivity, multiplexing capacity, spatial and temporal resolution. Moreover, most techniques are unable to provide information regarding the molecular tissue composition. In this review, we highlight the potential of Raman spectroscopy as a spectroscopic technique with high detection sensitivity and spatial resolution for distinguishing healthy from malignant margins in microscopic scale and in real time. A Raman spectrum constitutes an intrinsic “molecular finger-print” of the tissue and any biochemical alteration related to inflammatory or cancerous tissue state is reflected on its Raman spectral fingerprint. Nowadays, advanced Raman systems coupled with modern instrumentation devices and machine learning methods are entering the clinical arena as adjunct tools towards personalized and optimized efficacy in surgical oncology.

8 May 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
TSTheodoros A Sidiropoulos
Theodoros A Sidiropoulos
Nikolas DovrolisNikolas Dovrolis
Nikolas Dovrolis
HKHector Katifelis
Hector Katifelis
Nikolaos V. MichalopoulosNikolaos V. Michalopoulos
Nikolaos V. Michalopoulos
PKPanagiotis Kokoropoulos
Panagiotis Kokoropoulos
Maria GazouliMaria Gazouli
Maria Gazouli
Pancreatic cancer (PC) ranks as the seventh leading cause of cancer-related deaths, with approximately 500,000 new cases reported in 2020. Existing strategies for early PC detection primarily target individuals at high risk of developing the disease. Nevertheless, there is a pressing need to identify innovative clinical approaches and personalized treatments for effective PC management. This study aimed to explore the dysbiosis signature of the fecal microbiota in PC and potential distinctions between its Intraductal papillary mucinous neoplasm (IPMN) and pancreatic ductal adenocarcinoma (PDAC) phenotypes, which could carry diagnostic significance. The study enrolled 33 participants, including 22 diagnosed with PDAC, 11 with IPMN, and 24 healthy controls. Fecal samples were collected and subjected to microbial diversity analysis across various taxonomic levels. The findings revealed elevated abundances of Firmicutes and Proteobacteria in PC patients, whereas healthy controls exhibited higher proportions of Bacteroidota. Both LEfSe and Random Forest analyses indicated the microbiome’s potential to effectively distinguish between PC and healthy control samples but fell short of differentiating between IPMN and PDAC samples. These results contribute to the current understanding of this challenging cancer type and highlight the applications of microbiome research. In essence, the study provides clear evidence of the gut microbiome’s capability to serve as a biomarker for PC detection, emphasizing the steps required for further differentiation among its diverse phenotypes.

24 November 2023 in Journal of Imaging
Verified
Journal Article
Open access
PDF file
DKDimitris Kalatzis
Dimitris Kalatzis
Ellas SpyratouEllas Spyratou
Ellas Spyratou
MKMaria Karnachoriti
Maria Karnachoriti
Maria Anthi KouriMaria Anthi Kouri
Maria Anthi Kouri
ISIoannis Stathopoulos
Ioannis Stathopoulos
Efstathios P. EfstathopoulosEfstathios P. Efstathopoulos
Efstathios P. Efstathopoulos
Raman spectroscopy (RS) techniques are attracting attention in the medical field as a promising tool for real-time biochemical analyses. The integration of artificial intelligence (AI) algorithms with RS has greatly enhanced its ability to accurately classify spectral data in vivo. This combination has opened up new possibilities for precise and efficient analysis in medical applications. In this study, healthy and cancerous specimens from 22 patients who underwent open colorectal surgery were collected. By using these spectral data, we investigate an optimal preprocessing pipeline for statistical analysis using AI techniques. This exploration entails proposing preprocessing methods and algorithms to enhance classification outcomes. The research encompasses a thorough ablation study comparing machine learning and deep learning algorithms toward the advancement of the clinical applicability of RS. The results indicate substantial accuracy improvements using techniques like baseline correction, L2 normalization, filtering, and PCA, yielding an overall accuracy enhancement of 15.8%. In comparing various algorithms, machine learning models, such as XGBoost and Random Forest, demonstrate effectiveness in classifying both normal and abnormal tissues. Similarly, deep learning models, such as 1D-Resnet and particularly the 1D-CNN model, exhibit superior performance in classifying abnormal cases. This research contributes valuable insights into the integration of AI in medical diagnostics and expands the potential of RS methods for achieving accurate malignancy classification.

21 February 2025 in Talanta
Verified
Journal Article
Closed access
MKMaria Karnachoriti
Maria Karnachoriti
Maria Anthi KouriMaria Anthi Kouri
Maria Anthi Kouri
Ellas SpyratouEllas Spyratou
Ellas Spyratou
NDNikolaos Danias
Nikolaos Danias
Nikolaos ArkadopoulosNikolaos Arkadopoulos
Nikolaos Arkadopoulos
AKAthanassios G. Kontos
Athanassios G. Kontos

16 November 2023 in Cancers
Verified
Journal Article
Open access
PDF file
MPMARIA Papadoliopoulou
MARIA Papadoliopoulou
MMMaria Matiatou
Maria Matiatou
SKSpyridon Koutsoumpos
Spyridon Koutsoumpos
Francesk MulitaFrancesk Mulita
Francesk Mulita
PGPanagiotis Giannios
Panagiotis Giannios
Nikolaos V. MichalopoulosNikolaos V. Michalopoulos
Nikolaos V. Michalopoulos
Assessment of regional lymph node status in breast cancer is of important staging and prognostic value. Even though formal histological examination is the currently accepted standard of care, optical imaging techniques have shown promising results in disease diagnosis. In the present article, we review six spectroscopic techniques and focus on their use as alternative tools for breast cancer lymph node assessment. Elastic scattering spectroscopy (ESS) seems to offer a simple, cost-effective, and reproducible method for intraoperative diagnosis of breast cancer lymph node metastasis. Optical coherence tomography (OCT) provides high-resolution tissue scanning, along with a short data acquisition time. However, it is relatively costly and experimentally complex. Raman spectroscopy proves to be a highly accurate method for the identification of malignant axillary lymph nodes, and it has been further validated in the setting of head and neck cancers. Still, it remains time-consuming. Near-infrared fluorescence imaging (NIRF) and diffuse reflectance spectroscopy (DFS) are related to significant advantages, such as deep tissue penetration and efficiency. Fourier-transform infrared spectroscopy (FTIR) is a promising method but has significant drawbacks. Nonetheless, only anecdotal reports exist on their clinical use for cancerous lymph node detection. Our results indicate that optical imaging methods can create informative and rapid tools to effectively guide surgical decision-making.

Verified
Journal Article
Open access
PDF file
SCSpyridon Christodoulou
Spyridon Christodoulou
CSChristina Sotiropoulou
Christina Sotiropoulou
PVPanteleimon Vassiliu
Panteleimon Vassiliu
NDNikolaos Danias
Nikolaos Danias
Nikolaos ArkadopoulosNikolaos Arkadopoulos
Nikolaos Arkadopoulos
DSDiamantis C. Sideris
Diamantis C. Sideris
Colorectal cancer (CRC) is the main cause of cancer-related deaths globally, highlighting the importance of accurate biomarkers for early detection and accurate prognosis. MicroRNAs (miRNAs) have emerged as effective cancer biomarkers. The aim of this study was to investigate the prognostic potential of miR-675-5p as a molecular prognostic biomarker in CRC. For this reason, a quantitative PCR assay was developed and applied to determine miR-675-5p expression in cDNAs from 218 primary CRC and 90 paired normal colorectal tissue samples. To assess the significance of miR-675-5p expression and its association with patient outcome, extensive biostatistical analysis was performed. miR-675-5p expression was found to be significantly downregulated in CRC tissue samples compared to that in adjacent normal colorectal tissues. Moreover, high miR-675-5p expression was associated with shorter disease-free (DFS) and overall survival (OS) in CRC patients, while it maintained its unfavorable prognostic value independently of other established prognostic factors. Furthermore, TNM stage stratification demonstrated that higher miR-675-5p levels were associated with shorter DFS and OS intervals, particularly in patients with CRC of TNM stage II or III. In conclusion, our findings suggest that miR-675-5p overexpression constitutes a promising molecular biomarker of unfavorable prognosis in CRC, independent of other established prognostic factors, including TNM staging.